Suppr超能文献

益生菌大肠杆菌Nissle 1917与安慰剂治疗婴幼儿持续时间超过4天的腹泻。

Probiotic Escherichia coli Nissle 1917 versus placebo for treating diarrhea of greater than 4 days duration in infants and toddlers.

作者信息

Henker Jobst, Laass Martin W, Blokhin Boris M, Maydannik Vitaliy G, Bolbot Yuriy K, Elze Martina, Wolff Corinna, Schreiner Armin, Schulze Jürgen

机构信息

Department of Pediatrics, University Carl-Gustav-Carus, Dresden, Germany.

出版信息

Pediatr Infect Dis J. 2008 Jun;27(6):494-9. doi: 10.1097/INF.0b013e318169034c.

Abstract

BACKGROUND

Administering probiotics can prevent or cure some forms of diarrhea. The efficacy of probiotic Escherichia coli Nissle 1917 (EcN) in infants and toddlers with diarrhea >4 days was tested by a double-blind trial.

METHODS

One hundred fifty-one children aged 1-47 months with nonspecific diarrhea were randomized to receive either EcN suspension (N = 75) or placebo (N = 76). Diarrhea had to meet the following definition: >3 watery or loose nonbloody stools in 24 hours of a diarrheal episode persisting for >4 consecutive days but < or =14 days. All children were well nourished or only moderately malnourished, mildly dehydrated, and received oral rehydration at study commencement. They were treated orally with 1-3 mL EcN suspension (1 mL contains 10 viable cells) or placebo daily for 21 days. Primary objective was to confirm a better response rate (reduction of daily stool frequency to < or =3 watery or loose stools over > or =4 days) with EcN.

RESULTS

The 7-day response was higher for the EcN group than placebo (EcN 78.7%, placebo 59.2%). Significant differences were observed on days 14 (EcN 93.3%, placebo 65.8%, P = 0.0017) and 21 (EcN 98.7%, placebo 71.1%, P < 0.001). Kaplan-Meier survival analysis resulted in a significant difference of 3.3 days between the groups (P < 0.0001); median time to response for EcN was 2.4 and 5.7 for placebo. EcN was safe and well tolerated.

CONCLUSIONS

In the conditions of this trial EcN was a suitable remedy for diarrhea >4 days in young children.

摘要

背景

服用益生菌可预防或治愈某些类型的腹泻。通过一项双盲试验测试了益生菌大肠杆菌Nissle 1917(EcN)对腹泻超过4天的婴幼儿的疗效。

方法

151名年龄在1 - 47个月的非特异性腹泻儿童被随机分为两组,分别接受EcN悬浮液(N = 75)或安慰剂(N = 76)。腹泻必须符合以下定义:在持续超过4天但≤14天的腹泻发作期间,24小时内有>3次水样或稀软非血性大便。所有儿童营养状况良好或仅为中度营养不良,轻度脱水,且在研究开始时接受口服补液。他们每天口服1 - 3 mL EcN悬浮液(1 mL含10个活细胞)或安慰剂,持续21天。主要目的是确认EcN的反应率更高(在≥4天内将每日大便频率降至≤3次水样或稀软大便)。

结果

EcN组的7天反应率高于安慰剂组(EcN为78.7%,安慰剂为59.2%)。在第14天(EcN为93.3%,安慰剂为65.8%,P = 0.0017)和第21天(EcN为98.7%,安慰剂为71.1%,P < 0.001)观察到显著差异。Kaplan - Meier生存分析显示两组之间存在3.3天的显著差异(P < 0.0001);EcN的中位反应时间为2.4天,安慰剂为5.7天。EcN安全且耐受性良好。

结论

在本试验条件下,EcN是治疗幼儿腹泻超过4天的合适药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验